Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Concert Pharmaceuticals, Inc. (Private) |
|
|
“The vision behind Concert is to take a different tack at drug discovery that would enable the creation of new chemical entities (NCEs), first-and best-in-class new medicines, in a way that substantially reduces the risks associated with current drug development approaches and increases the likelihood of their successful commercial development.” - Roger Tung, Ph.D. (Interview published February 19, 2009) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Oct. 20, 2009 7:30 ET
Concert Pharmaceuticals to Present at Second Annual Boston Biotech R&D Conference
2009 Boston Biotech R&D Conference
LEXINGTON, Mass.--(BUSINESS
WIRE)--
Concert
Pharmaceuticals, Inc. today announced that it
will be presenting at the 2009 Boston Biotech R&D
Conference being held at
Harvard
Medical School in
Boston, Massachusetts. Roger Tung, Ph.D.,
President and
Chief Executive Officer will present an overview
of the Company
on Tuesday, October 27, 2009 at 1:40 p.m. (ET).
About Concert Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. Its lead development candidate is the HIV protease inhibitor CTP-518. In 2009, Concert entered into a potential $1 billion collaboration with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com. About the Boston Biotech R&D Conference The 2009 Boston Biotech R&D Conference will highlight up-and-coming biotech companies in the Boston area. The agenda features several luminaries in medicine and research, as well as executives of the next generation of leading biotech and pharma companies from the Boston area. Jonathan Kraft, president and chief operating officer of The Kraft Group, will provide the keynote address. The conference is being organized by Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, a GSK company and Senior Vice President of the Center of Excellence for External Drug Discovery (CEEDD), GSK and Michelle Dipp, M.D., Ph.D., Vice President, Head of U.S. CEEDD, GSK. The conference is sponsored by Alexandria Real Estate Equities, Clinquest, MassBio, Massachusetts Life Sciences Center, Merriman Curhan Ford & Co., Pure Communications, Inc. For more information, visit www.bostonbiotechconference.com. Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert Pharmaceuticals, Inc. Contacts
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284 Senior Director, Corporate Communications and Investor Relations jkoenigsberg@concertpharma.com Source: Concert Pharmaceuticals, Inc.
|
|
